Browse studies

Find your next paid study

3,218 recruiting studies matching your filters

EV-PRIME: Phase Ib/II Study of Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy as a Bladder-Sparing Trimodality Therapy in Muscle Invasive Bladder Cancer

This phase Ib/II trial studies the side effects, best dose, and effectiveness of enfortumab vedotin (EV) in combination with pembrolizumab and radiation therap…

Bladder CancerMuscle-Invasive Bladder CarcinomaStage II Bladder Cancer AJCC v8+1 more

Estimated

~$150 – $2,700

Actual pay is set by the research site.

University of California, San FranciscoNCT06470282

Phase 2

An Integrated Intervention Using a Pill Ingestible Sensor System to Trigger Actions on Multifaceted Social and Behavioral Determinants of Health Among PLWH

This study integrates technology-based adherence measures with alerts for social and behavioral determinants of health (SBDOH) to improve HIV treatment outcome…

HIV/AIDSMedication AdherenceSocial Determinants of Health (SDOH)

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of California, Los AngelesNCT06480578

Phase 1

A Phase 1, Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B455 in Patients With Selected Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to learn if BGB-B455 can treat advanced or metastatic solid tumors expressing claudin 6 (CLDN6), a protein that is found on …

Advanced Solid TumorMetastatic Solid Tumor

Estimated

~$150 – $4,500

Actual pay is set by the research site.

BeOne MedicinesNCT06803680

Phase 1

Phase 1/2a Open-label Clinical Trial Evaluating VBC108, a CLDN18.2 and CDH17-directed Bi-specific Antibody Drug Conjugate, in Participants With Advanced Malignant Solid Tumors

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion uses Bayesian optimal interval (BOIN) design to escalate and determ…

Advanced Solid Tumors

Estimated

~$150 – $4,200

Actual pay is set by the research site.

VelaVigo Bio IncNCT07700160

Phase 1

A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients With Pancreatic Ductal Adenocarcinoma

This early phase I trial aims to determine how cobimetinib, olaparib, onvansertib, azenosertib, AZD5305 or tremelimumab works in patients with pancreatic cance…

Locally Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage II Pancreatic Cancer AJCC v8+5 more

Estimated

~$150 – $4,500

Actual pay is set by the research site.

OHSU Knight Cancer Institute

A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies

Background: Tumors in the genitourinary tracts can occur in the kidney, bladder, prostate, and testicles and can have common and rare histologies. Some cancer…

Urothelial CancerBladder CancerGenitourinary Cancer+2 more

Estimated

~$10 – $675

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT04923178

Phase 1

A Phase I Trial of Intraperitoneal Mesothelin-Targeted CAR T Cell Therapy in Patients With Mesothelin-Positive Esophagogastric Adenocarcinoma With Peritoneal Carcinomatosis or Malignant Peritoneal Mesothelioma

Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sen…

Mesothelin PositiveMesothelin-Expressing TumorsEsophageal Adenocarcinoma+5 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT06623396

Phase 1

MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer

This study is a prospective, open-label, phase I design.

Rectal Adenocarcinoma

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Medical College of WisconsinNCT04808323

Observational

Investigating Changes in Premonitory Urges During Habit Reversal Training

The primary aim of this study is to learn more about premonitory urges (PU) when using Habit Reversal Training (HRT) to treat tics. The main focus of this stu…

TicsTourette DisorderTourette Syndrome in Children+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

University of UtahNCT06825520

Phase 1

A Phase 1/2, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are …

Locally Advanced/Metastatic Solid Tumors

Estimated

~$150 – $4,200

Actual pay is set by the research site.

InSilico Medicine Hong Kong LimitedNCT06414460

Lidocaine Infusion As A Treatment Modality For Headache Following Non-Traumatic Subarachnoid Hemorrhage: A Prospective, Single-Center, Observational Cohort Study

The goal of this observational study is to evaluate intravenous lidocaine efficacy and safety in treating headache following non-traumatic subarachnoid hemorrh…

Subarachnoid; Hemorrhage, NontraumaticHeadache

Estimated

~$10 – $750

Actual pay is set by the research site.

University of Kansas Medical CenterNCT06582810

Phase 1

A Phase 1a/1b Open Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of DBC-664 in Adult Patients With Locally Advanced or Metastatic Solid Tumors

DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-t…

Malignant Germ Cell TumorLung AdenocarcinomaGastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma+3 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Duboce Biopharmaceuticals, Inc.NCT07705035